Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics
Demographics (1)
- Age - Age at Randomization (phv00294391.v1.p1)
Disease Events (11)
- AFFECTION_STATUS - Case control status of the subject for Pathologic Complete Response (phv00294380.v1.p1)
- CNS - Clinical Nodal Status (phv00294386.v1.p1)
- CTS - Clinical Tumor Size (phv00294385.v1.p1)
- ER - Estrogen Receptor Status (phv00294392.v1.p1)
- Grade - Histologic Tumor Grade (phv00294395.v1.p1)
- HR - Hormone Receptor Status (phv00294387.v1.p1)
- NAT_Complete - Completion of neoadjuvant therapies by protocol (phv00294397.v1.p1)
- PgR - Progesterone Receptor Status (phv00294393.v1.p1)
- Response - Best response status (phv00294398.v1.p1)
- TLFUP - Time to last follow-up in years (phv00294399.v1.p1)
- TOFF - Time to the first DFS event (including recurrent, second primary and death) (phv00294401.v1.p1)
Medications (3)
- Bevacizumab - Bevacizumab Treatment (phv00294390.v1.p1)
- Capecitabine - Capecitabine Treatment (phv00294389.v1.p1)
- Gemcitabine - Gemcitabine Treatment (phv00294388.v1.p1)
Race and Ethnicity (1)
- Race - Race (phv00294394.v1.p1)
Other (15)
- ANALYTE_TYPE - Analyte Type (phv00294405.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00294404.v1.p1)
- Breast - Side of cancer (phv00294396.v1.p1)
- CDFS - Censoring code for TOFF (phv00294402.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00294379.v1.p1)
- DEATH - Censoring code for death (phv00294400.v1.p1)
- GENOTYPING_CENTER - Name of the center which conducted genotyping (phv00294408.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00294407.v1.p1)
- IS_TUMOR - Tumor status (phv00294406.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00294403.v1.p1)
- SAMPLE_ID - Sample ID (phv00294382.v1.p1)
- SAMPLE_USE - Sample Use (phv00294383.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00294384.v1.p1)
- SUBJECT_ID - Subject ID (phv00294378.v1.p1)
- SUBJECT_ID - Subject ID (phv00294381.v1.p1)